These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 525009)

  • 61. [Differential diagnosis of scleroderma-like changes in the skin].
    Pokorný M
    Cesk Dermatol; 1973 Oct; 48(5):347-50. PubMed ID: 4762465
    [No Abstract]   [Full Text] [Related]  

  • 62. [Nervous system changes in children and adults with systemic scleroderma].
    Demidova PV; Ivanova KV; Mozolevskiĭ IuV
    Sov Med; 1971 Sep; 34(9):6-11. PubMed ID: 5121298
    [No Abstract]   [Full Text] [Related]  

  • 63. [Relationship between systemic and circumscribed scleroderma].
    Dovzhanskiĭ SI; Nikiforova NE; Slesarenko NA
    Vestn Dermatol Venerol; 1976 Jan; (1):60-4. PubMed ID: 997865
    [No Abstract]   [Full Text] [Related]  

  • 64. [Sclerodermiform skin diseases].
    Thies W
    Med Welt; 1976 Oct; 27(41):1941-6. PubMed ID: 792618
    [No Abstract]   [Full Text] [Related]  

  • 65. Scleroderma--developing measures of response.
    Furst DE; Khanna D; Mattucci-Cerinic M; Silman AJ; Merkel PA; Foeldvari I;
    J Rheumatol; 2005 Dec; 32(12):2477-80. PubMed ID: 16331791
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Age-sex aspects of distribution of children with scleroderma according to clinical forms].
    Popik GS
    Pediatriia; 1990; (12):81-2. PubMed ID: 2075074
    [No Abstract]   [Full Text] [Related]  

  • 67. [Pseudoscleroderma and scleroderma-like states].
    Thivolet J
    Rev Prat; 1975 May; 25(25):1959-63. PubMed ID: 1135585
    [No Abstract]   [Full Text] [Related]  

  • 68. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Diagnosis of systemic scleroderma].
    Guĭda PP
    Klin Med (Mosk); 1983 Jun; 61(6):82-5. PubMed ID: 6887774
    [No Abstract]   [Full Text] [Related]  

  • 70. Increased protocollagen proline hydroxylase activity in sclerodermatous skin.
    Keiser HR; Stein HD; Sjoerdsma A
    Arch Dermatol; 1971 Jul; 104(1):57-60. PubMed ID: 5120163
    [No Abstract]   [Full Text] [Related]  

  • 71. [Calcification in scleroderma (contribution to the so-called Thiebierge-Weissenbach syndrome)].
    Kolár J; Drugová B; Stáva Z
    Sb Lek; 1971 Oct; 73(10):258-63. PubMed ID: 5137493
    [No Abstract]   [Full Text] [Related]  

  • 72. A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.
    McCann LJ; Pain CE
    Indian J Pediatr; 2016 Feb; 83(2):163-71. PubMed ID: 26489640
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The clinical heterogeneity of the scleroderma group of diseases].
    Guseva NG
    Ter Arkh; 1992; 64(8):109-12. PubMed ID: 1440384
    [No Abstract]   [Full Text] [Related]  

  • 74. [Scleroderma. Its various forms].
    Escande JP
    Nouv Presse Med; 1974 Mar; 3(9):537-8. PubMed ID: 4822162
    [No Abstract]   [Full Text] [Related]  

  • 75. [Localized scleroderma: its position in sclerodermal disease].
    Belaich S
    Rev Prat; 1975 May; 25(25):1947-8, 1951-5. PubMed ID: 1135584
    [No Abstract]   [Full Text] [Related]  

  • 76. Scleroderma: a case presentation.
    Otterness S
    Nephrol Nurs J; 2005; 32(4):454-6. PubMed ID: 16180790
    [No Abstract]   [Full Text] [Related]  

  • 77. Clinical manifestations of scleroderma.
    Haber PL
    Pediatr Rev; 1995 Feb; 16(2):49. PubMed ID: 7877909
    [No Abstract]   [Full Text] [Related]  

  • 78. Serum renin and renin substrate levels in scleroderma.
    Fleischmajer R; Gould AB
    Proc Soc Exp Biol Med; 1975 Nov; 150(2):374-9. PubMed ID: 1208551
    [No Abstract]   [Full Text] [Related]  

  • 79. Early identification key to scleroderma treatment.
    Joslin N
    Nurse Pract; 2004 Jul; 29(7):24-39; quiz 40-1. PubMed ID: 15238856
    [No Abstract]   [Full Text] [Related]  

  • 80. Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment.
    Li SC; O'Neil KM; Higgins GC
    J Pediatr; 2021 Jul; 234():245-256.e2. PubMed ID: 33548257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.